This could be due to the high heterogeneity between studies which included genetic-based and toxin-based PD models and the use of a variety of cannabinoids (two CBR agonists, three MAGL/FAAH inhibitor or endocannabinoid modulator) or more significantly, had variations in how the open field tests were undertaken in each included study. This evidence concerns the gene MGLL and Parkinson disease.